Heart Failure Clinical Trial

Identifying Markers of Exercise Training in Heart Failure

Summary

The heart failure syndrome that occurs when the heart is too sick to properly do its job. One of the main symptoms is difficulty with exercise. One way to improve symptoms is to start patients in a 12 week exercise program called cardiac rehabilitation. Cardiac rehabilitation been shown to improve symptoms for heart failure patients. However, we do not know exactly what exercise does to the molecules that make up the human body. If we could answer this question, we might find a whole new way to treat the symptoms of heart failure. Therefore we want to know what molecules might be responsible for the benefits of exercise. The plan for this study is to measure the levels of thousands of proteins in blood samples which come from people with heart failure and see how those levels change after 12 weeks of cardiac rehabilitation, compared to the protein levels in patients whose cardiac rehabilitation is delayed until after the study period. If we know the proteins that change with exercise, we can then look to see if targeting these proteins with medicines can mimic the benefits of exercise. The long term goal of our work is to identify "exercise-in-a-pill" medicines that will help people with heart failure.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 18-89
Patients must carry a diagnosis of heart failure with ejection fraction < 40%
Be willing to participate in cardiac rehabilitation, and not already done so in the last year
Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
Have a CPET in the last 6 months
Must be able to exercise on a treadmill

Exclusion Criteria:

Inability to complete CPET or participate in CR (verbal/chart)
Syncope during CPET within the last 6 mos, sustained VT on CPET, hemodynamically significant arrhythmia during CPET (verbal/chart)
BMI >= 38 (verbal/chart)
History of a bleeding disorder or clotting abnormality (verbal/chart)
Clinical diagnosis of severe Chronic Obstructive Pulmonary Disease (COPD) (verbal/chart)
History of malignancy not considered in remission (verbal/chart)
Cirrhosis (verbal/chart)

Thyroid disease (verbal/chart)

Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory within the last 1 year

Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting
Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment

Cancer (verbal/chart)

History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years
Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months

Chronic active or latent infection (verbal/chart)

Active or latent infections requiring chronic antibiotic or anti-viral treatment
Chronic active infection whether on chronic antimicrobials or not
Human Immunodeficiency Virus
Active hepatitis B or C undergoing antiviral therapy
Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded

Tobacco (verbal/chart)

Current smokers: any tobacco or e-cigarette/e-nicotine products
Former smokers: Stopped smoking <6 months at time of screening
Not be pregnant or lactating in the last 12 months, or planning to become pregnant for the next 4 months. Not be post-partum during the last 12 months. (verbal/chart)
Metabolic bone disease (self-report): History of non-traumatic fracture from a standing height or less. Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen. (verbal/chart)
Diabetes (self-report and screening), which includes: i) treatment with any insulin or ii) A1c >=8.0 (screening). (verbal/chart)
Chronic renal insufficiency (screening): estimated glomerular filtration rate <30 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation. (verbal/chart)
Individuals receiving any active treatment for autoimmune disorders (including monoclonal antibodies) within the last 6 months. (verbal/chart)
Alcohol consumption: i) more than 7 drinks per week for women and more than 14 drinks per week for men; ii) history of binge drinking. (verbal/chart)
Any individual engaging in night shift work in the last 6 months.
Hospitalization for any psychiatric condition within one year (verbal/chart)
Any musculoskeletal or ligamentous injury, amputation or congenital neurological defect that, in the opinion of the team clinician, would negatively impact or mitigate participation in and completion of the protocol. (verbal/chart)
Mental incapacity and/or cognitive impairment on the part of the participant that would inhibit adequate understanding of or cooperation with the study protocol

Other (clinician judgment)

Genetic metabolic disorders that could affect metabolomic results (e.g., phenylketonuria)
Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol
Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol

Medication exclusions (chart review)

Androgenic anabolic steroids, antiestrogens, antiandrogens
Growth hormone, insulin like growth factor, growth hormone releasing hormone
Insulin of any type used regularly
Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise induced muscle hypertrophy

Psychiatric

Chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines; short-acting non-benzodiazepine sedative-hypnotics are allowed
Two or more drugs for depression
Mood stabilizers
Antiepileptic drugs
Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs
Anti-psychotic drugs
Narcotics and narcotic receptor agonists
Chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc) for any reason
High-potency topical steroids if ≥10% of surface area using rule of 9s
Continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention
Monoclonal antibodies
Anti-rejection medications/immune suppressants
Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion.

Study is for people with:

Heart Failure

Estimated Enrollment:

90

Study ID:

NCT05696652

Recruitment Status:

Recruiting

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford Health Care
Stanford California, 94305, United States More Info
Mia Levanto
Contact
650-498-5673
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

90

Study ID:

NCT05696652

Recruitment Status:

Recruiting

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.